With the annual American Society of Clinical Oncology meeting reduced to virtual sessions and other events commanding the country’s attention, oncology hasn’t been dominating the newsflow as it usually does in late spring. The US Food and Drug Administration’s approval of new indications for Genentech Inc.’s Tecentriq (atezolizumab) and Cyramza (ramucirumab) gave Roche and Eli Lilly & Co., respectively, something to talk about.
AstraZeneca PLC trumpeted FDA’s approval of a new indication for its anticoagulant Brilinta (ticagrelor) to reduce the risk of...





